Navigation Links
Evotec Reports Third Quarter 2007 Results
Date:11/13/2007

Evotec AG (Frankfurt Stock Exchange: EVT) Reported Today Results for the First Nine Months of 2007.

HAMBURG, Germany and OXFORD, England, November 13 /PRNewswire-FirstCall/ --

Highlights:

- Financials in-line with Evotec's full year expectations

- Compelling results achieved in two proof-of-concept Phase II trials with lead insomnia drug candidate EVT 201

- Sale of the Chemical Development Business to Aptuit and the proposed Renovis acquisition further emphasize the strategic transformation of Evotec towards a drug discovery and development company

- Merger will create a global company with three clinical candidates, a strong late stage preclinical pipeline focusing on areas of neurological and inflammatory diseases, and a strong cash position; expected to close in Q1 2008

- Expected year-end cash position increased to EUR 93-98 million, not yet including Renovis' cash

All amounts discussed in this press release are related to Evotec's continuing operations. The discontinued operations and a discussion of the business sold to Aptuit are provided in Evotec's full Third Quarter Report.

Revenues for the first nine months of 2007 were EUR 23.2 million, 23% below last year's level (2006: EUR 29.9 million). The decline is the consequence of (i) lower milestone income compared to the same period last year (approximately - EUR 3 million), (ii) the reduction of the library synthesis business following the transfer of this business into a joint venture with RSIL (reduction of EUR 4.0 million or 82%), and (iii) decline of the US dollar against Evotec's reporting currency Euro. At constant 2006 currencies (UK Sterling and US dollar), revenues would have been approximately one million higher (EUR 24.1 million). Excluding these three extraordinary effects Evotec's remaining business performed strongly, growing 6% from EUR 21.9 million for the first nine months of 2006 to EUR 23.2 million for the first nine months 2007.<
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its results ... complete second quarter financial statements and MD&A have been filed on ... per shareThree-months ended , Six -months endedJune 30 , June 30 ... 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 , ...
(Date:8/27/2015)... ... 2015 , ... Inc. Magazine released its annual list of the 5,000 fastest-growing ... growth for the three years through 2014. Being named to the Inc. 5000 list ... the country. , “We are thrilled to make the Inc. 5000 list for ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... Personalized Medicine, recently presented new data on the relationship of genetics and hypertension ... World Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, which ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3
... Jayne Garno, LSU associate professor of chemistry in the ... government,s highest honor for scientists and engineers in the ... Early Career Award for Scientists and Engineers, or PECASE. ... a prestigious award. LSU is a rich environment for ...
... DIEGO, Nov. 10, 2010 Anadys Pharmaceuticals, Inc. (Nasdaq: ... the Lazard 7th Annual Healthcare Conference on Wednesday, November 17, ... is being held at the St. Regis New York.  Steve ... provide an overview of Anadys and its clinical development programs. ...
... Dendreon Corporation (Nasdaq: DNDN ) today ... the post-approval supplement to the PROVENGE® (sipuleucel-T) Biologics ... manufacturing facility. Dendreon is requesting licensure for an ... U.S. Food and Drug Administration (FDA) review for ...
Cached Biology Technology:LSU’s Jayne Garno receives early career award from President 2Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference 2Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility 2
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s touch ... 2015 that relate to sales of FPC1155 for this smartphone model ... for 2015. Jörgen Lantto, CEO of FPC, comments: " ... manufacturer in China and we are proud ... for Z1 , its first ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... Listed below are the selected highlights for the November 2012 ... . The November issue is available online at ... November 2012, Copyright 2012. Please feel free to ... ISSUE HIGHLIGHTS , An ex vivo model ...
... metro region from Super Storm Sandy has not yet ... PhD, PE, says when the hammers start swinging, it,s ... The material, best known as AAC, has been heralded ... It,s a lightweight, easily-crafted manufactured stone, strong enough to ...
... researchers have discovered the cellular pathway that causes lung-damaging ... pathway,s activity also decreases inflammation. The finding offers ... disease, which is a major cause of illness and ... that target lung inflammation would be a big step ...
Cached Biology News:Genetics Society of America's GENETICS journal highlights for November 2012 2Genetics Society of America's GENETICS journal highlights for November 2012 3Genetics Society of America's GENETICS journal highlights for November 2012 4New drug target found for cystic fibrosis lung disease 2
... Anti-PSD-95, clone K28/86.2, PDZ Domain ... Immunogen : GST fusion to residues ... 0.01M Tris pH 7.4, 0.075M NaCl ... routinely evaluated by immunoblot on rat ...
... • Small design specifically for western blots ... are specifically designed for staining western blots. ... 25 mm) of the disposable tray requires ... significant cost savings to the user. Pour ...
... software has been designed and created in ... biologist friendly genotyping analysis tool. We incorporated ... groups into the software. Their main requirements ... and low acquisition cost. GeneMarker can ...
...
Biology Products: